-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KKr+ocvlSFNVVnpREyOr1c7Zs4PFofigAUlITqOoUfxjOUSfV2RIPl1jRU6nSYOs 3oo1VyfcJDeLncLmgyuDlw== 0000950133-05-005212.txt : 20060925 0000950133-05-005212.hdr.sgml : 20060925 20051115134109 ACCESSION NUMBER: 0000950133-05-005212 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20051115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVAVAX INC CENTRAL INDEX KEY: 0001000694 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222816046 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 508 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 4849131200 MAIL ADDRESS: STREET 1: 508 LAPP ROAD CITY: MALVERN STATE: PA ZIP: 19355 CORRESP 1 filename1.htm corresp
 

November 15, 2005
Via Facsimile and U.S. Mail
Jim B. Rosenberg, Senior Assistant Chief Accountant
Joel Parker, Accounting Branch Chief
Dana Hartz, Staff Accountant
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
         
  Re:   Novavax, Inc.
      Form 10-K/A for the Fiscal Year Ended December 31, 2004
      Filed March 15, 2005
      File No. 000-26770
Dear Messrs. Rosenberg and Parker and Ms. Hartz:
     On behalf of Novavax, Inc. (the “Company”), following my telephone conversation with Ms. Hartz, I am writing to modify our response to the third comment in your letter dated July 12, 2005 with respect to the above referenced filing (the “Filing”). This letter supplements and expands our response letters dated July 26, 2005 and October 31, 2005.
Concurrence with Comment 3
     Per our telephone conversation at the end of August of this year, you requested in future filings that Novavax segregate its sales returns allowance provisions related to sales for the current period from the provisions relating to sales from prior periods. The Company concurs with that request and will initiate the requested level of detail and disclosure in future filings, beginning with our annual report on Form 10-K for the fiscal year ended December 31, 2005. It was also our understanding following our telephone conversation that if the Company’s rebates continue to be an insignificant amount as a percentage of sales or net income, the Company is permitted to simply note the amount and/or percentage and not provide the roll-forward detail as required for sales returns. The Company therefore will continue this practice in future filings.

 

 

Mr. Jim Rosenberg, Mr. Joel Parker and Ms. Dana Hartz
Securities and Exchange Commission
November 15, 2005
Page 2
     The Company acknowledges that (a) the Company is responsible for the adequacy and accuracy of the disclosure in the Filing; (b) staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking action with respect to the Filing; and (c) the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
     Please do not hesitate to call me at (484) 913-1203 if you have any additional comments or questions.
         
  Yours sincerely,




Dennis W. Genge
Chief Financial Officer
 		  
     
     
     
 

 

-----END PRIVACY-ENHANCED MESSAGE-----